Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?

(1) Background: Piperacillin-tazobactam represents the first-line option for treating infections caused by full- or multi-susceptible <i>Enterobacterales</i> and/or <i>Pseudomonas aeruginosa</i> in critically ill patients. Several studies reported that attaining aggressive ph...

Full description

Bibliographic Details
Main Authors: Milo Gatti, Matteo Rinaldi, Tommaso Tonetti, Antonio Siniscalchi, Pierluigi Viale, Federico Pea
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Antibiotics
Subjects:
piperacillin-tazobactam
continuous infusion
critically ill patients
Gram-negative infections
joint PK/PD target attainment
expert clinical pharmacological advice
Online Access:https://www.mdpi.com/2079-6382/12/12/1736

Similar Items

Similar Items